Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in PediatricKMT2A-Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531 | Zendy

Jessica A. Pollard | Zendy; Erin Guest | Zendy; Todd A. Alonzo | Zendy; Robert B. Gerbing | Zendy; Mike R. Loken | Zendy; Lisa Eidenschink Brodersen | Zendy; E. Anders Kolb | Zendy; Richard Aplenc | Zendy; Soheil Meshinchi | Zendy; Susana C. Raimondi | Zendy; Betsy Hirsch | Zendy; Alan S. Gamis | Zendy

Open Access

Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in PediatricKMT2A-Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531

Author(s) -

Jessica A. Pollard,

Erin Guest,

Todd A. Alonzo,

Robert B. Gerbing,

Mike R. Loken,

Lisa Eidenschink Brodersen,

E. Anders Kolb,

Richard Aplenc,

Soheil Meshinchi,

Susana C. Raimondi,

Betsy Hirsch,

Alan S. Gamis

Publication year - 2021

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.20.03048

Subject(s) - medicine , gemtuzumab ozogamicin , oncology , overall survival , genetics , stem cell , cd34 , cd33 , biology

We investigated the impact of the CD33-targeted agent gemtuzumab ozogamicin (GO) on survival in pediatric patients with KMT2A -rearranged ( KMT2A -r) acute myeloid leukemia (AML) enrolled in the Children's Oncology Group trial AAML0531 (NCT01407757).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research